{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:23:32Z","timestamp":1788791012420,"version":"build-2803163510"},"reference-count":29,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To study the efficacy and safety of ixekizumab (IXE) in patients with radiographic (r-) and non-radiographic (nr-)axial spondyloarthritis (axSpA) for up to 116 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      COAST-Y (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03129100\">NCT03129100<\/jats:ext-link>\n                      ) is the 2-year extension study following COAST-V, COAST-W and COAST-X. Patients were treated with either 80\u2009mg IXE every 4 weeks or 2 weeks, as assigned in the originating studies. Efficacy was assessed in all participants continuously treated with IXE through week 116 and in subgroups based on disease subtype and dosing. Missing data were handled by non-responder imputation for categorical variables and modified baseline observation carried forward for continuous variables. Safety data were analysed in all patients having received \u22651 IXE dose.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 932 patients who received \u22651 IXE dose, 773 enrolled in COAST-Y (82.9%); 665 of which (86.0%) completed week 116. Of 352 continuously treated patients, the proportion achieving Assessment of Spondyloarthritis International Society (ASAS40) at week 52 was 51.4%, which increased to 56.0% at week 116. The proportion of patients achieving ASAS40 at week 116 was 64.9% and 57.7% for biological disease-modifying antirheumatic drug (bDMARD)-na\u00efve patients with r-axSpA and nr-axSpA, respectively, and 47.0% for TNFi-experienced patients. The proportion of patients achieving Ankylosing Spondylitis Disease Activity Score &lt;2.1 through week 116 was 57.0% and 52.9% for bDMARD-na\u00efve patients with r-axSpA and nr-axSpA, respectively, and 33.6% for TNFi-experienced patients. Incidences of treatment-emergent adverse events and serious adverse events were consistent with previous reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IXE treatment led to sustained long-term improvements in patients with axSpA, with similar efficacy for r-axSpA and nr-axSpA, and for patients receiving the approved every 4 weeks dose. The safety profile of IXE was consistent with previous reports. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-002165","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T12:45:32Z","timestamp":1658234732000},"page":"e002165","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03129100","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03129100","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02696785","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02696798","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02757352","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-5095","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Braun","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, and Department of Biochemistry, Ruhr Universit\u00e4t, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, and Department of Biochemistry, Ruhr Universit\u00e4t, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-6229","authenticated-orcid":false,"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hopital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bolce","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sandoval","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yen","family":"Lin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Walsh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"2025090312423786000_8.2.e002165.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025090312423786000_8.2.e002165.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108217"},{"key":"2025090312423786000_8.2.e002165.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215707"},{"key":"2025090312423786000_8.2.e002165.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208852"},{"key":"2025090312423786000_8.2.e002165.5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001108"},{"key":"2025090312423786000_8.2.e002165.6","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000337","article-title":"Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis","volume":"93","author":"Kilic","year":"2014","journal-title":"Medicine"},{"key":"2025090312423786000_8.2.e002165.7","doi-asserted-by":"crossref","first-page":"A523.2","DOI":"10.1136\/annrheumdis-2013-eular.1566","article-title":"FRI0439\u2005High economic burden of axial spondyloarthritis related to paid work and household productivity at baseline in the rapid-axspa study: differences and similarities between ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"72","author":"van der Heijde","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025090312423786000_8.2.e002165.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090312423786000_8.2.e002165.9","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and Nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312423786000_8.2.e002165.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446"},{"key":"2025090312423786000_8.2.e002165.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333"},{"key":"2025090312423786000_8.2.e002165.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"2025090312423786000_8.2.e002165.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"2025090312423786000_8.2.e002165.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"2025090312423786000_8.2.e002165.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh584"},{"key":"2025090312423786000_8.2.e002165.16","doi-asserted-by":"crossref","first-page":"714.1","DOI":"10.1136\/annrheumdis-2014-eular.1696","article-title":"SAT0337\u2005Clinical Response and Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy: Table 1","volume":"73","author":"van der Heijde","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025090312423786000_8.2.e002165.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190299"},{"key":"2025090312423786000_8.2.e002165.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.40753"},{"key":"2025090312423786000_8.2.e002165.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32971-X"},{"key":"2025090312423786000_8.2.e002165.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"2025090312423786000_8.2.e002165.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216118"},{"key":"2025090312423786000_8.2.e002165.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.3824"},{"key":"2025090312423786000_8.2.e002165.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210023"},{"key":"2025090312423786000_8.2.e002165.24","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21688"},{"key":"2025090312423786000_8.2.e002165.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"2025090312423786000_8.2.e002165.26","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312423786000_8.2.e002165.27","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","article-title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","volume":"56","author":"van der Heijde","year":"2017","journal-title":"Rheumatology"},{"key":"2025090312423786000_8.2.e002165.28","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025090312423786000_8.2.e002165.29","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatology"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-002165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:42:45Z","timestamp":1756928565000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-002165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,19]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/rmdopen-2021-002165"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-002165","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}